Lipid Panel Test Market Estimated to Flourish by 2015 – 2023

Lipid Panel Test Market: Overview

Anti-inflammatory peptides also known as antiflammins inhibit inflammation of a mammal’s skin, lacerations of the musculature, mucous membranes, or injury into the air spaces of the lungs. Anti-inflammatory peptides act by hindering synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions. Anti-Inflammatory peptides are used to treat diseases such as psoriasis, multiple sclerosis, inflammatory bowel disease and other autoimmune diseases.

Download PDF Brochure of Report:

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5813

Moreover, other tests can also be deployed in addition for a CHD risk factor analysis such as apolipoprotein B (apo B) test. Apo B is a protein molecule, which primarily constitutes lipoproteins like VLDL & LDL.  Apo B test is usually conducted under special circumstances along with an Apo A and routine lipid profile, which determines an individual’s risk of developing CHD, in cases where there is a family history of CHDs along with elevated triglyceride levels due to overactive lipid metabolism. The concentration of Apo A-I is directly proportional to HDL levels and is found to have a strong correlation with CHD.LPT also provides the ratio among different values for TC to HDL-C (TC/HDL-C) and the ratio of LDL-C to HDL-C (LDL-C/HDL-C) which can be used as markers for a risk factor analysis.

The evidence in favor of potential growth in the LPT market can be related with two main factors. First, screening and identification of population with moderate to high risk and for their follow up in later stages. The second factor would be LPT routine testing for monitoring clinical and subclinical cases of lipid disorders. Lipid disorder is one of the risk factors for CHD, necessitating prompt diagnosis through LPT among those who have family history of CHD. Moreover, middle age group men and women collectively form the moderate to high-risk population. Thus, LPT market has a tremendous scope if used as a screening tool for rapid diagnosis of lipid and its associated disorders due to rising disease burden. This epidemiologic transition is evident from the prevalence rate of diet-related chronic diseases, which have become the major killers.

Request to View TOC of Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=5813

The lipid panel test market can be segmented based on its application into disease segments, hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia, hyperlipoproteinemia, and tangier disease. End users include home based testing kits, diagnostic laboratories, hospitals, and others (CROs, Public Health Institutions).

The potential drivers in the market include higher funding from government and global healthcare institutions such as the World Health Organisation (WHO) for screening programs to identify at-risk population and dyslipidemia diagnosis. The other demand side factors include high prevalence of dyslipidemia, cardiovascular diseases, and hypertension. However, some of the restraints are attributed to healthcare reforms such as the Affordable Health Care for America Act, which will curb high healthcare costs, reducing the profit margins for those operating in the industry. Moreover, there are global initiatives to curb out-of-pocket health expenditure for chronic diseases. Similarly, future prospects for growth in Germany remains blunt due to cost cutting strategies in their public insurance program for clinical testing or pathology payments.

Some of the major players in the lipid panel test market include Abbott Laboratories, Alere Inc., Avanti Polar Lipids, Inc., Beckman Coulter, Inc., EuroMedixPOC nv/sa, F. Hoffmann-La Roche Ltd, PTS Diagnostics, Quest Diagnostics, Randox Laboratories Ltd., and Thermo Fisher Scientific Inc.

Request For Discount On This Report:
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=5813

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.